Alle Storys
Folgen
Keine Story von Pieris AG mehr verpassen.

Pieris AG

Takeda San Francisco and Pieris Sign Anticalin® Therapeutic Collaboration

San Francisco, USA and Freising, Germany (ots)

Takeda San
Francisco (TSF) and Pieris AG have signed a drug discovery 
partnership agreement under which Pieris will apply its Anticalin® 
scaffold technology to deliver protein therapeutic candidates to 
Takeda, both companies announced today.  The deal initially will 
focus on first-in-class drug discovery efforts around a predetermined
Takeda target.  The collaboration includes an option for expansion 
following delivery of a successful candidate to Takeda, which would 
lead subsequent development and commercial efforts.  Further deal 
terms and financial details were not disclosed.
"TSF?s mandate is to lead Takeda?s effort in the discovery and 
preclinical development of antibody-based therapeutics.  Pieris? 
Anticalin technology complements our existing capabilities by 
enabling a novel approach to targets where differentiation from 
traditional antibodies is required,? stated Dr. Mary Haak-Frendscho, 
President and CSO of TSF. "The technology provides unique features 
that made Pieris the obvious partner.?
"Our agreement with Takeda demonstrates yet again that Anticalins 
can fill gaps left by more conventional technologies such as 
monoclonal antibodies,? added Stephen Yoder, CEO of Pieris. "Pieris 
is committed to maintaining an effective balance between developing 
our internal therapeutic pipeline and collaborating with world-class 
organizations like Takeda.?
Pieris? proprietary Anticalin technology platform creates next 
generation targeted therapeutics and addresses targets in ways that 
traditional methods cannot.  Anticalins are recombinantly engineered 
lipocalins, endogenous low-molecular weight human proteins that 
naturally bind, store and transport a wide spectrum of molecules. To 
obtain a specific Anticalin, Pieris applies its deep protein 
engineering know-how to select drug candidates from its suite of 
rationally designed proprietary Anticalin libraries.
About Takeda San Francisco, Inc. Takeda San Francisco, Inc. (TSF),
established in November 2007 as a wholly owned subsidiary of Takeda 
Pharmaceutical Company Limited, Osaka, Japan, is Takeda?s Biologics 
Center of Excellence and Antibody IND Engine for human antibody 
therapeutics for the treatment of cancer, inflammation and metabolic 
diseases. TSF supports Takeda?s therapeutic antibody initiative in 
close collaboration with Takeda?s other R&D organizations. Additional
information about Takeda San Francisco is available at 
http://www.takedasf.com.
--more--
About Takeda Pharmaceutical Company, Limited Located in Osaka, 
Japan, Takeda is a research based global company with its main focus 
on pharmaceuticals. As the largest pharmaceutical company in Japan 
and one of the global leaders of the industry, Takeda is committed to
striving toward better health for patients worldwide through leading 
innovation in medicine. Additional information about Takeda is 
available through its corporate website, http://www.takeda.com.
About Pieris Pieris AG is an independent, clinical-staged 
biotechnology company advancing its proprietary Anticalin? technology
to create safer, more efficacious and more convenient protein 
therapeutics.  Exclusive to Pieris, Anticalin-based drugs promise to 
address high-unmet medical needs and expand the therapeutic potential
of current targeted approaches.  Pieris? pipeline ranges from its 
Phase I compound, PRS-050 (anti-VEGF, oncology), to multiple 
Anticalins in preclinical development.  In addition to Takeda, the 
company has a multi-year, multi-target collaboration with 
Sanofi-Aventis and Sanofi Pasteur, the vaccines division of the 
sanofi-aventis Group (EURONEXT: SAN and NYSE: SNY), and an agreement 
with Allergan, Inc. (NYSE: AGN), focusing on novel treatments for eye
diseases.  Privately held, Pieris has been funded by premier 
biotechnology-focused venture capital, including lead investors 
OrbiMed Advisors and Global Life Science Ventures.  For more 
information, please visit: www.pieris-ag.com.
For more information, please contact
For Pieris: 
Stephen Yoder 
Chief Executive Officer 
Tel: +49 (0) 8161-1411-400
or
Kari Watson 
MacDougall Biomedical Communications 
Tel: +1-781-235-3060
For Takeda San Francisco: 
Patricia Sinatra 
Corporate Communications and Public Relations 
285 E. Grand Avenue 
South San Francisco, CA 94080 
Tel: +1-650-745-9486

Weitere Storys: Pieris AG
Weitere Storys: Pieris AG
  • 07.06.2010 – 10:17

    Pieris AG Appoints Chief Scientific Officer

    Freising-Weihenstephan (ots) - Pieris AG announced today that Laurent Audoly, Ph.D., has joined the company as Chief Scientific Officer, effective immediately. Dr. Audoly, most recently Biologics Research Site Lead at Merck & Co. Inc., brings both pharma and biotech experience, with extensive expertise in therapeutic protein drug development. "Laurent has an impressive track record of leading teams and ...